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Imiquimod Leads to a Decrease of Human
Papillomavirus DNA and to a Sustained Clearance of
Anal Intraepithelial Neoplasia in HIV-Infected Men
Alexander Kreuter1,4, Anja Potthoff1, Norbert H. Brockmeyer1, Thilo Gambichler1, Markus Stu¨cker1,
Peter Altmeyer1, Jochen Swoboda2, Herbert Pfister3 and Ulrike Wieland3,4 for the German Competence
Network HIV/AIDS
Anal intraepithelial neoplasia (AIN), a human papillomavirus (HPV)-associated precursor lesion of anal
carcinoma, is highly prevalent in HIV-infected men having sex with men (MSM). This prospective follow-up
study evaluated the long-term results of imiquimod treatment of AIN in 19 HIV-infected MSM. Standardized
follow-up examinations included high-resolution anoscopy, anal cytology/histology, HPV typing, and DNA load
determination for HPV types 16, 18, 31, and 33. Mean follow-up time was 30.3 months. A total of 74% (14/19) of the
patients remained free of AIN at the previously treated site. Five patients (26%) had recurrent high-grade AIN
after a mean time of 24.6 months. At the end of follow-up, the numbers of HPV types as well as high-risk
HPV–DNA loads were significantly lower than before therapy. During follow-up, 58% of all patients (11/19)
developed new anal cytological abnormalities in previously normal, untreated anal regions. 55% of these new
AIN lesions were high-grade lesions and most of them were located intra-anally and associated with high-risk
HPV types not detectable before therapy. These results demonstrate that imiquimod leads to a high rate of long-
term clearance of AIN in HIV-positive men together with a prolonged decrease of high-risk HPV–DNA load.
However, new AIN lesions associated with previously undetected HPV types frequently occur in untreated areas.
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INTRODUCTION
Human papillomavirus (HPV) infections are widespread and
cause a broad spectrum of benign and malignant epithelial
lesions. At least 40 HPV types, belonging to the genus
Alphapapillomavirus, have been shown to infect the anogenital
mucosa. High-risk (or carcinogenic) HPV types, such as HPV16
and HPV18, are frequently found in high-grade intraepithelial
neoplasia and invasive cancer (Munoz et al., 2003). Some low-
risk HPV types, such as HPV6 and HPV11, cause genital warts.
In immunocompetent individuals, most anogenital HPV infec-
tions are eliminated by the immune system within a few
months, whereas immunodeficiency is a risk factor for
persistent HPV infection. Consistent with this, anal HPV
infection is present in most HIV-infected men having sex with
men (MSM), and infections with multiple HPV types are
common (Palefsky et al., 1998a). Consequently, HPV-asso-
ciated anogenital malignancies occur with high frequency in
this high-risk population (Palefsky et al., 2005). The use of
highly active anti-retroviral therapy led to a significant
reduction of most opportunistic infections, whereas the impact
of highly active anti-retroviral therapy on HPV infection is
limited (Palefsky et al., 2005). Anal carcinoma might be
prevented by early detection and treatment of its precursor
lesion, anal intraepithelial neoplasia (AIN) (Chiao et al., 2006).
To date, internationally accepted treatment standards for AIN
are still missing, and commonly used ablative strategies (for
example, surgical excision, electrosurgery, or laser therapy)
might lead to considerable morbidity (Chin-Hong and Palefsky,
2002; Abbasakoor and Boulos, 2005; Fox, 2006).
Imiquimod is a topical immune response modifier with
antitumoral and antiviral activity that is being used for the
treatment of benign and malignant cutaneous tumors as genital
warts, actinic keratoses, basal cell, and squamous cell
carcinomas (Scho¨n and Scho¨n, 2006). We recently published
a pilot study on imiquimod treatment for AIN in HIV-infected
MSM. Close to 80% of patients, who applied imiquimod as
instructed, showed a complete clearance of AIN lesions at the
end of therapy (Wieland et al., 2006). The present prospective
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follow-up study was initiated to evaluate the long-term
outcome in these patients using clinical, cytological, and
virological criteria.
RESULTS
Clinical, cytological, and histopathological long-term results
after imiquimod treatment of AIN
Nineteen HIV-positive MSM were included in this prospective
follow-up study: 16 men with complete histological clearance
of AIN after 16 weeks of imiquimod treatment as well as three
patients (patients 1, 19, 20) with residual AIN1 after 16 weeks
of imiquimod therapy who developed a normal clinical status
and normal cytology within the first three months of follow-up.
The mean follow-up time was 30.3 months (range: 11–39,
median: 32 months). All long-term results are depicted in
Table 1. At the last follow-up visit, 74% (14/19) of patients had
normal cytology and a normal clinical status at the anal area
previously treated. One patient (patient 3) had a transient low-
grade squamous intraepithelial lesion (LSIL) cytology (that was
not treated) 5 months after the end of therapy, but was
cytologically and clinically normal thereafter until the end of
follow-up. Five patients (26%) developed a recurrence
of high-grade AIN at the site of treatment (four patients
had AIN2 and one had AIN3). Mean time until recurrence in
these patients was 24.6 months (range: 11–37, median: 27
months). The clinical presentation of recurrent AIN was
identical with the pretreatment AIN type in all cases (three
patients with leukoplakic, one patient with bowenoid, and one
with verrucous AIN). In contrast to the patients remaining free
of relapsing AIN at the treated site, those with recurrent AIN all
had a history of opportunistic infections. Moreover, patients
with recurrent AIN had a significantly lower CD4 cell count
nadir (mean: 49ml1, range: 10–141ml1) than those without
(mean: 279ml1, range: 48–655ml1; P¼ 0.0079).
Eleven of the 19 patients (58%) developed new cytological
abnormalities in the previously normal untreated anal area
(that is, intra-anal lesions in patients with previous perianal
imiquimod treatment and vice versa). Almost all of the new
AIN lesions (10/11; 91%) were located intra-anally (Table 1;
Figure 1). Six of the 11 patients (55%) with new lesions had
high-grade anal dysplasia (HSIL/AIN2/3), and five patients
showed low-grade anal dysplasia (Table 1). There was no
significant difference in the CD4 cell count nadirs of patients
with and without new AIN development at previously
untreated sites (P¼ 0.9). When looking at both anal sites, six
patients (32%) had normal perianal and intra-anal cytology
and a normal high-resolution anoscopy (HRA) status at the end
of follow-up. Four patients (21%) had a normal treated site, but
had low-grade squamous intraepithelial lesion (LSIL) at the
previously untreated anal site, and nine patients (47%) had
high-grade AIN at one or both anal sites (Table 1). All patients
with recurrent or new AIN were offered (re)treatment with
imiquimod, or if they declined this, with electrocautery (for
verrucous AIN) or 85% trichloroacetic acid (for flat AIN).
HPV spectrum and HPV–DNA load at the end of follow-up
Before imiquimod treatment all patients had been high-risk
HPV–DNA-positive (Wieland et al., 2006). At the end of
follow-up, 74% (14/19) were high-risk HPV–DNA-positive,
11% (2/19) carried only low-risk HPV types, and 16% (3/19)
were HPV–DNA-negative at the previously treated site
(Table 1). The most frequent high-risk types were HPV16
(9/16; 56%), HPV33, HPV35, and HPV58 (4/16; 25%,
respectively). A total of 81% (13/16) of the HPV-positive
patients were infected with more than one HPV type (range:
1–9 HPV types, mean: 3.4 HPV types) at the site previously
treated. There was no significant change in the number
of HPV types at the end of therapy compared with the end of
the follow-up period (P¼ 0.8); however, the number of HPV
types at the end of follow-up was still significantly lower than
that before therapy (P¼0.026).
When looking at the previously not affected untreated anal
site (intra-anal in patients with previous perianal AIN and
vice versa), only one patient with a CD4 count of 726 ml1
(patient 9) was HPV–DNA-negative at both anal sites at the
end of follow-up. The remaining 18 patients were HPV–DNA-
positive at the previously untreated site and all of them
carried high-risk types (Table 1). Interestingly, in most
patients (9/11, 82%) with anal dysplasia at the untreated
site, (additional) high-risk HPV types that had not been
detected before therapy were found. This was also the case
in two of the patients with recurrent AIN at the treatment
site (patients 6 and 12; Table 1).
Concerning high-risk HPV–DNA loads at the treated site at
the end of follow-up, 10 patients carried at least one of the
four high-risk types quantified in this study (Table 1). Most
patients kept the low HPV–DNA loads they had at the end of
therapy during the follow-up period, and no significant
change in HPV–DNA loads could be observed (P¼ 1.0).
High-risk HPV–DNA loads at the end of the follow-up period
still were significantly lower than those before therapy
(P¼0.003). Only 2 of the 14 patients (patients 4 and 19)
with normal cytology/HRA status at the previously treated site
showed a rise in viral load at the end of follow-up, but also in
these patients end-of-follow-up loads were lower than
pretreatment loads (Table 1). In patients with recurrent AIN
(and quantifiable HPV types) an increase of high-risk
HPV–DNA loads compared with the loads at the end of
therapy was seen (Table 1). Interestingly, in a couple of
patients with new high-grade AIN at previously untreated
sites, viral loads of some newly detected high-risk types that
had not been found before treatment, were higher than those
of high-risk types already detected before treatment. In patient
26, the perianal DNA load of the newly detectable HPV type
33 was 15 copies/b-globin gene copy, whereas loads of HPV
types, that had been present before therapy, were below
detection limit of quantitative PCR for HPV16 and three
copies/b-globin gene copy for HPV18. Similarly, patient 17
had a low intra-anal HPV16 load of 0.6 copies, whereas that
of the newly detectable HPV33 was 23 copies/b-globin gene
copy. In patient 4, the intra-anal HPV16-load was five copies
and HPV31 load was 33 copies/b-globin gene copy, but the
load of the second newly detected type, HPV33, was not
higher than the HPV16 load. However, in the perianal end-of-
follow-up sample of this patient, HPV33 load was higher than
HPV16 load (30 copies vs 3 copies/b-globin gene copy).
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Table 1. Clinical, cytological, histological, and virological characteristics of imiquimod-treated patients
Patient
no.
Localization
of AIN,
histology
before and at
the end of tx
HPV types
before
therapy
Duration of
follow-up1
(months)
Clinical/HRA
status at
treated site
at end of
follow-up
Cytology/
histology at
the treated
site at end
of follow-up
Time until
recurrence
of AIN
HPV types
at treated
site at last
follow-up
HPV–DNA
load2 before
therapy3/at
the end of
therapy3/at
the last
follow-up
Anal
dysplasia at
previously
untreated
site
HPV types
at
previously
untreated
site
27 P-AIN1-n 16 33 Normal n — 16, 35 205/12/1 I-HSIL/AIN2 I-16, 35
6 P-AIN1-n 33, 52, 58 36 Leukoplakic
AIN
HSIL/AIN2 36 33, 35 17,634/HPV-
neg./0.01
I-normal I-16, 35
14 P-AIN1-n 16, 18, 33, 58,
59, 89
37 Normal n — 11, 35, 52,
53, 54, 61,
82, 84, 89
0.2/HPV-
neg./no qt
I-normal I-11, 16, 18,
58
25 P-AIN1-n 33, 52, 58, 59,
89
27 Normal n — HPV-neg. 0.1/0.3/
HPV-neg.
I-normal I-16
13 P-AIN1-n 61, 66, 73 33 Normal n — 82 no qt/0/no qt I-HSIL/AIN2 I-82
4 P-AIN2-n 16, 54 32 Normal n — 16, 33, 52,
58
365/3/34 I-HSIL/AIN3 I-16, 31, 33
3 I-AIN2-n 16, 18, 31, 33,
35, 42, 45, 52,
59, 66, 70, 83,
89
29 Normal n — 42, 43, 45,
52, 66, 73
17/1/no qt P-normal P-42, 45, 52
16 P-AIN2-n 16, 18, 52, 83 12 Leukoplakic AIN HSIL/AIN2 12 16, 18 16,073/22/1340 I-HSIL/AIN3 I-16, 18
12 P-AIN2-n 11, 16, 18, 42 37 Bowenoid AIN HSIL/AIN2 37 58, 73 1,092/111/no qt I-LSIL I-16, 18, 31,
33, 42, 44,
51, 58, 68
17 P-AIN3-n 16 27 Normal n — 16, 33 1,859/31/8 I-HSIL/AIN2 I-16, 33, 82
18 P-AIN3-n 16 32 Normal n — 43 139/15/no qt I-LSIL I-51
26 I-AIN3-n 11, 16, 18, 31,
58
11 Verrucous AIN HSIL/AIN3 11 11, 16, 18,
58, 83
41/0.2/2 P-HSIL/AIN3 P-16, 18, 33,
83
10 P-AIN3-n 16 32 Normal n — HPV-neg. 2/0/HPV-neg. I-normal I-16, 34, 54,
73, 81
8 P-AIN3-n 16, 34, 73 39 Normal n — 16 193/0/0.003 I-LSIL I-33
9 P-AIN3-n 53, 56 34 Normal n — HPV-neg. no qt/HPV-
neg./HPV-neg.
I-normal HPV-neg.
23 I-AIN3-n 6, 16, 18, 44, 83,
89
27 Leukoplakic
AIN
HSIL/AIN2 27 6, 16, 18 35/2/29 P-normal P-16, 18
20 P-AIN1-AIN1 16, 35, 40, 42,
52, 59, 66, 70,
72, 81, 84
27 Normal n — 70, 72, 81 ne/no qt/no qt I-normal I-35, 70, 72,
81, 89
19 P-AIN3-AIN1 16, 18, 33, 35,
52, 58, 68, 83,
89
33 Normal n — 16, 31, 33,
35, 45, 58,
68
772/HPV-
neg./29
I-LSIL I-16, 18, 26,
45, 58, 68
1 P-AIN3-AIN1 16, 42, 45, 59 38 Normal n — 16, 42, 84,
89
ne/no qt/2 I-LSIL I-16, 42, 45,
84, 89
AIN, anal intraepithelial neoplasia; HPV, human papillomavirus; HPV-neg., HPV–DNA negative; HRA, high-resolution anoscopy; HSIL, high-grade
squamous intraepithelial lesion; I, intra-anal; LSIL, low-grade squamous intraepithelial lesion; n, normal; ne, not evaluable because cellular input was too
low; no qt, no quantifiable types (HPV-types other than HPV16, 18, 31 or 33) were present; no., number; P, perianal; tx, therapy.
1The follow-up observation period ended in case of recurrence of AIN at the treated site.
2HPV–DNA load is the cumulative load of HPV16, 18, 31, and 33, if the respective types were present. HPV–DNA load is defined as HPV–DNA copies per
b-globin gene copy.
3See Wieland et al. (2006).
HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 were considered as high-risk HPV types, and HPV6, 11, 34, 40, 42, 43, 44, 54,
57, 61, 70, 72, 81, 83, 84, and 89 as low-risk HPV types (Munoz et al., 2003).
Underlined are high-risk HPV types that were not detectable before imiquimod therapy.
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DISCUSSION
AIN is very frequent in HIV-positive MSM and these patients
have a strongly increased risk for the development of anal
cancer (Palefsky et al., 2005; Hessol et al., 2007). Therefore,
screening programs to detect and treat anal cancer precursor
lesions at an early stage have been recommended (Chin-Hong
and Palefsky, 2002). This study was performed to evaluate the
long-term results of imiquimod treatment of AIN in HIV-positive
MSM. Only the subset of patients from the pilot trial that were
compliant and had a complete response to therapy with
imiquimod were included (Wieland et al., 2006). The main
finding was that 74% of patients who had completely cleared
their AIN after imiquimod therapy remained free of recurrences
at the treated anal region during the complete follow-up period.
When comparing our results with other treatment options for
AIN, only studies including more than 10 individuals irrespec-
tive of the patients’ sex and immune status were considered.
Interventions for AIN comprised therapeutic HPV vaccines
(Klencke et al., 2002; Palefsky et al., 2006), surgical ablation
(Chang et al., 2002; Pineda et al., 2007), and infrared
coagulation (Goldstone et al., 2005, 2007). Two studies
included HIV-positive patients only (Goldstone et al., 2005;
Palefsky et al., 2006), three studies HIV-negative patients only
(Klencke et al., 2002; Goldstone et al., 2007; Pineda et al.,
2007), and one study both (Chang et al., 2002). HIV-negative
patients showed a better response to treatment and a lower
recurrence rate of AIN, a finding most likely related to the
impaired host immune function in HIV infection. When
comparing studies that included HIV-positive individuals, our
long-term results compare favorably with other treatment
options for AIN. The relapse rate after imiquimod treatment
found in this study was 26%, whereas both surgical ablation
(79% persistent or recurrent HSIL; Chang et al., 2002) and
infrared coagulation (65% new or persistent intra-anal HSIL;
Goldstone et al., 2005) showed higher rates of recurrences after
the first intervention. Our results are in line with a recent study
of imiquimod treatment for genital warts/AIN1 in HIV-positive
individuals that reported a relapse rate of 29% in patients who
had cleared their lesions (Sanclemente et al., 2007). Mean
follow-up time in the study performing surgical treatment (28.6
months) was comparable to our study, whereas the follow-up
period of the study using infrared coagulation (median: 14
months) was shorter (Chang et al., 2002; Goldstone et al.,
2005). Therapeutic vaccination induced regression of high-
grade AIN in a quarter to a third of patients (Klencke et al.,
2002; Palefsky et al., 2006). Thus, therapeutic vaccination could
be an interesting adjunct to topical or ablative AIN treatment.
A large number of patients in this study initially had perianal
disease, whereas AIN in the other trials was located intra-anally.
Peri- and intra-anal dysplasia is histologically and immunohis-
tochemically indistinguishable (Welton et al., 2001), but the
difference in location is important, since intra-anal disease is
more difficult to treat for anatomical reasons. Furthermore,
intra-anal lesions can be overlooked behind hypertrophied anal
papillae, between hemorrhoids, and in crypts. Thus, the higher
recurrence rates in studies using ablative techniques (surgical
or infrared coagulator ablation) might, at least in part, be
explained by the intra-anal location of AIN. This could also
explain the worse long-term outcome using imiquimod for
intra-anal disease, as two of the three patients (patients 23 and
26) with intra-anal AIN had recurrent disease in our study.
We have previously reported that imiquimod treatment of
AIN leads to a significant decline of high-risk HPV–DNA loads
and to a reduction of the number of HPV types at the end of
therapy (Wieland et al., 2006). In the follow-up of these patients,
high-risk HPV–DNA loads remained at low levels (no significant
differences compared with the post-treatment status), and at the
end of follow-up, high-risk HPV–DNA loads still were signifi-
cantly lower than before therapy. The same applied to the
number of HPV types. This observation could indicate an
imiquimod-induced Th1 response, which has also been reported
after imiquimod treatment of genital warts or vulvar intraepithe-
lial neoplasia (Arany et al., 1999; van Poelgeest et al., 2005).
Possible reasons for recurrence of AIN in five of our patients
could be infections with new high-risk HPVs (patients
6 and 12), increases in high-risk HPV–DNA loads (patients 16
and 23) or unknown host genomic mutations (Weissenborn et al.
2003; Gagne et al., 2005). Interestingly, these five patients had
statistically significant lower CD4 cell count nadirs than those
without AIN recurrence, probably reflecting a more compro-
mised immune status. A similar trend towards an increased risk
for AIN development in HIV-positive men with low CD4 cells
a b
c d
Figure 1. Clinical presentation of intra-anal dysplasia developing during
the follow-up period. HRA was performed as described under Materials
and Methods. (a) Normal squamocolumnar junction without any signs of
HPV-related disease (patient 14) is shown for comparison. (b) Anal dysplasia
(AIN2). Large, dark red area that starts bleeding easily. The lesion is
slightly raised and shows very discrete vascular structures. Opaque areas
are seen with distributed punctuation and mosaic. The periphery shows
mild degrees of whitening (patient 17). (c) Anal dysplasia (AIN2).
Homogenous, well-demarcated, hyperkeratotic area with a granular
surface surrounded by normal squamous epithelium (patient 23). (d) Anal
dysplasia (AIN3). Large hyperkeratotic area with some smaller satellite
lesions. The surface of the lesion is granular and focally spiked and
shows variations in the amount of keratin (patient 4).
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has been published recently (Palefsky et al., 2005). Although it is
hypothetical to draw any general conclusions from these
observations, severely immunodeficient patients might be more
predisposed to recurrences of anal dysplasia and may benefit
from more frequent follow-up examinations.
During the follow-up period, 58% of patients developed
new anal dysplasia of any grade and 32% high-grade AIN at
previously untreated anal sites. Most of these new AIN lesions
were located intra-anally. It was recently reported that only
half of the patients with AIN had visible lesions undergoing
standard anoscopy, demonstrating that HRA is indispensable
in screening, treatment, and follow-up of high risk popu-
lations for anal dysplasia (Watson et al., 2006; Pineda et al.,
2007). Interestingly, (additional) high-risk HPV types that
were not present before therapy were found in most of the
new lesions. Since these high-risk types were not detectable
when imiquimod was applied, it is conceivable that they
escaped the induction of a type-specific Th1 response. The
high prevalence of new AIN lesions is in line with previous
studies showing that AIN is frequent and transformation from
normal to dysplastic epithelium occurs fast in HIV-positive
men (Palefsky et al., 1998b, 2005; Lacey et al., 1999). None
of the studies on ablative treatment for anal dysplasia in
HIV-positive MSM included HPV typing and HPV–DNA load
determination. Therefore, it remains unclear if the occurrence
of new high-risk HPV types at high viral loads in new AIN
lesions is a particular finding in imiquimod-treated patients.
In conclusion, this follow-up study demonstrated that
imiquimod leads to a high rate of long-term clearance of AIN
and to a prolonged decrease of high-risk HPV–DNA loads in
complete responders compliant with treatment. In view of the
high prevalence of AIN in HIV-positive MSM, controlled
studies comparing imiquimod with other treatment options
for AIN should be initiated.
MATERIALS AND METHODS
Patients and previous treatment with imiquimod
Nineteen HIV-infected MSM with either perianal or intra-anal AIN
were included in this follow-up study. All patients were previously
treated with imiquimod 5% cream (Aldara; 3M Medica, Borken,
Germany) or imiquimod containing suppositories, depending on
the localization of AIN, three times a week overnight for 16 weeks
as recommended for the treatment of genital warts. All patients’
clinical, immunological (CD4 cell count), and virological (lesional
HPV spectrum and HPV–DNA loads, HIV viral load in plasma)
characteristics have been reported previously (Wieland et al., 2006).
This previous trial comprised 28 HIV-positive MSM. Six (patients 2,
5, 11, 22, 24, 28) of these 28 patients were incompliant and did not
apply imiquimod at all or only occasionally at a few time points, two
patients were lost to follow-up (patients 7 and 15), and one patient
(patient 21) had residual AIN2 after treatment. In this study, only
compliant patients with complete clearance of AIN at the end
of therapy or within the first three months thereafter were included.
The follow-up period ranged from 11 to 39 months (mean: 30.3
months, median: 32 months). Follow-up visits were scheduled every
3–6 months. The mean was six follow-up visits per patient. Eighteen
patients were successfully treated with highly active anti-retroviral
therapy during the entire follow-up period. CD4 counts in these
patients ranged between 197 and 1010 ml1 (mean: 529 ml1), and
HIV-1 RNA loads were below 40 copiesml1 in all of them at the
last follow-up visit. One patient (patient 16) refused taking highly
active anti-retroviral therapy, resulting in a CD4 count of 78 ml1 and
an HIV-1 RNA load of 134,000 copiesml1 at the end of follow-up.
The study was a sub-study of the German Competence Network
HIV/AIDS (grant no. 01KI0501). The protocol of the study was
approved by the Ethical Review Board of the Ruhr-University of
Bochum, and the study was conducted according to the Declaration
of Helsinki Principles. Informed consent at each clinical visit was
obtained from every patient included.
Clinical follow-up examination, HRA, and cytological and
histopathological evaluation
All participants underwent a standardized HPV screening program
at the Department of Dermatology at the Ruhr-University Bochum,
as previously described (Berry et al., 2004; Kreuter et al., 2005).
Clinical examination included inspection of the oral cavity, glans
penis, corona, sulcus, frenulum, inner part of the foreskin, scrotum,
and inguinal folds. The anal region was inspected in dorsal lithotomy
position. Dacron-tipped swabs were obtained for perianal and intra-
anal cytology, HPV typing, and HPV–DNA load determination.
Cytology results were classified according to the Bethesda system
as normal, ASCUS (atypical squamous cells of undetermined
significance), LSIL (low-grade squamous intraepithelial lesion),
HSIL (high-grade squamous intraepithelial lesion), or invasive cancer
(Crothers, 2005). A cytologist with high experience in reading anal
cytology analyzed all smears without knowledge of the clinical
status. For sample collection, swabs were moistened in water,
inserted into the anal canal until a resistance was met at the distal
rectum wall, and carefully rotated in a circular motion. A second
swab was obtained from the perianal skin. Thereafter, a wooden
cotton swab soaked in 3% acetic acid was rolled on the surface of
the perianal skin and then placed into the anal canal and remained
there for two minutes. A disposable plastic anoscope (Cooper
Surgical, Trumbull, CT) was then inserted into the anal canal. While
looking through the binoculars of a conventional colposcope
(Kolposkop 150 FC; Zeiss, Oberkochen, Germany) at a distance of
about 30 cm, the entire circumference of the distal rectum and anal
epithelium, squamous–columnar transitional zone (dentate line), and
perianal area was visualized in 30-fold magnification (Figure 1).
All clinically suspicious lesions were biopsied with either
endoscopic forceps (Hildyard post nasal forceps 3.5mm; GYRUS
ENT LCC, Bartlett, TN) at the intra-anal location or with conven-
tional punch biopsy under local anesthesia at the perianal location.
AIN was histologically categorized into three grades of disease
(confined to the lower third, lower two-thirds, or full thickness of the
epithelium) as previously described (Fenger and Nielsen, 1986). Two
blinded histopathologists evaluated the histopathological results
independently. In case of discrepancies, a third observer assessed
all specimens. AIN was clinically classified into four different
types (leukoplakic, erythroplakic, bowenoid, and verrucous AIN)
as previously described (Kreuter et al., 2005).
HPV analyses
HPV–DNA screening was performed with a highly sensitive group-
specific nested PCR with degenerate primers A5/A10 and A6/A8 as
previously described (Wieland et al., 2006). For HPV typing, internal,
2082 Journal of Investigative Dermatology (2008), Volume 128
A Kreuter et al.
Imiquimod Treatment of AIN
biotinylated A6/A8-PCR products were hybridized with 37 type-specific
digoxigenin-labeled oligonucleotide probes in an enzyme-immuno
assay (Jacobs et al., 1997). HPV–DNA load determinations were
performed by real-time PCR with type-specific primers and probes for
HPV types 16, 18, 31, and 33 as described before (Weissenborn et al.,
2003). HPV–DNA loads were expressed as HPV–DNA copies per
b-globin gene copy. If more than one of the four quantified HPV types
were present in a sample, cumulative HPV–DNA loads were calculated.
Statistical analysis
Data analysis was performed using the statistical package MedCalc
Software (Mariakerke, Belgium). Distribution of data was assessed by
the D’Agostino–Pearson test. For comparison of number of HPV types
and HPV–DNA load, we used Kruskal–Wallis analysis of variance and
post hoc Wilcoxon test (paired, non-normally distributed data). For
comparison of AIN development/recurrence with respect to CD4 cell
count, we used Student’s t-test (independent, normally distributed
data). A P-value less than 0.05 was considered significant.
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